NCT04326218 (IHMN) is a NA clinical trial of Blood sample in Membranous Nephropathy, sponsored by Centre Hospitalier Universitaire de Nice.

Who is sponsoring NCT04326218?

NCT04326218 is sponsored by Centre Hospitalier Universitaire de Nice.

What drugs are being tested in NCT04326218?

Interventions in NCT04326218: Blood sample.

What condition does NCT04326218 study?

NCT04326218 studies Membranous Nephropathy.

Is NCT04326218 still recruiting?

NCT04326218 is currently status unknown. Last updated 7 April 2020.

Last reviewed 2020-04-07 · How we verify

NCT04326218: IHMN

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunopathological Analysis in a French National Cohort of Membranous Nephropathy

Status unknown NA Last updated 7 April 2020

What this trial tests

NA trial testing Blood sample in Membranous Nephropathy in 400 participants. Status unknown.

Timeline

1 July 2020

Primary endpoint
1 July 2024

1 July 2024

Quick facts

Lead sponsor	Centre Hospitalier Universitaire de Nice
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	screening
Enrollment	400
Start date	1 July 2020
Primary completion	1 July 2024
Estimated completion	1 July 2024

Drugs / interventions tested

Blood sample — full drug profile →

Conditions studied

Membranous Nephropathy — all drugs for Membranous Nephropathy →

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

18 and older, any sex, with Membranous Nephropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

National cohort of all cases of membranous nephropathy (MN) during a 1 year period in France, based on a pathological and/or serological diagnostic, collecting the data on: * incidence of MN * prevalence of anti-PLA2R1 and anti-THSD7A * clinical outcome one year after diagnosis or after relapse (complete remission, partial remission or persistent nephrotic syndrome) * environmental risk factors for the onset of MN * HLA markers * patient care status in France

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses.
Cremoni M, Brglez V, Perez S, Decoupigny F, et al · · 2020 · cited 46× · PMID 33324398 · DOI 10.3389/fimmu.2020.574997
Toxic Occupational Exposures and Membranous Nephropathy.
Cremoni M, Agbekodo S, Teisseyre M, Zorzi K, et al · · 2022 · cited 18× · PMID 36283759 · DOI 10.2215/cjn.02930322
Optimization of Rituximab Therapy in Adult Patients With PLA2R1-Associated Membranous Nephropathy With Artificial Intelligence.
Destere A, Teisseyre M, Merino D, Cremoni M, et al · · 2024 · cited 12× · PMID 38312797 · DOI 10.1016/j.ekir.2023.10.023
Anti-Rituximab Antibodies Occurrence and Clinical Outcomes in Patients With Primary Membranous Nephropathy.
Allinovi M, Teisseyre M, Accinno M, Finocchi C, et al · · 2025 · cited 8× · PMID 40814630 · DOI 10.1016/j.ekir.2025.04.059

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

NCT07226466 — Evaluating Biomarkers of Cognitive Dysfunction in Patients With Cancer · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07030205 — Resting-state Imaging and OSteoporosiS · NA · recruiting
NCT07295808 — Identification and Characterisation of IgA With Nephritogenic Potential in IgA Deposition Nephropathies (Rep-IgAN) · NA · recruiting

Other recruiting trials for Membranous Nephropathy

Currently open trials in the same condition.

NCT07389499 — A Clinical Study Evaluating the Safety and Efficacy of GT719 Universal Cell Injection in the Treatment of Immune-mediate · EARLY_PHASE1 · recruiting
NCT06341205 — Personalized Rituximab Treatment Based on Artificial Intelligence in Membranous Nephropathy (iRITUX) · Phase 3 · recruiting
NCT05732402 — An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular Diseases · Phase 1, PHASE2 · active not recruiting
NCT05688865 — Correlation and Clinical Utility of Urinary Biomarker in Membranous Glomerulonephritis · recruiting
NCT04571658 — NEPTUNE Match Study · NA · recruiting

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

NCT05897996 — Percutaneous Anastomosis Creation for Hemodialysis Access · NA · withdrawn
NCT07499869 — INNOVATIVE BENEFITS OF A 4D VIRTUAL SIMULATOR · NA · not yet recruiting
NCT07492251 — Upadacitinib in Adult Patients With Erosive Mucosal Lichen Planus and Lichen Planopilaris: a Prospective Multicenter Ran · Phase 2 · not yet recruiting
NCT07511608 — Development of a New Technique for Quantifying Mitochondrial DNA in Single Muscle Fibers · NA · not yet recruiting
NCT07582406 — Codesign, Physical Activity, and Seniors · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04326218 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centre Hospitalier Universitaire de Nice
Last refreshed: 7 April 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04326218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing